Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-26EMA Authorised: Bysumlog (insulin lispro) — Gan & Lee Pharmaceuticals Europe GmbH
EMA authorised Bysumlog (insulin lispro) by Gan & Lee Pharmaceuticals Europe GmbH for diabetes mellitus.
-
EMA approval · 2026-08-25EMA Authorised: Ozempic (semaglutide) — Novo Nordisk A/S
The EMA has authorized Ozempic (semaglutide) from Novo Nordisk A/S for the therapeutic area of diabetes mellitus.
-
EMA approval · 2026-08-25EMA Authorised: Liraglutide STADA (liraglutide) — STADA Arzneimittel AG
The EMA authorises Liraglutide STADA (liraglutide) for diabetes mellitus, with STADA Arzneimittel AG as the marketing authorization holder.
-
EMA approval · 2026-08-21EMA Authorised: Ondibta (insulin glargine) — Sandoz GmbH
Authorisation of Ondibta (insulin glargine) by Sandoz GmbH for diabetes mellitus.
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: Dysvascular Amputation Self-Management of Health [NA]
Completed clinical trial results on self-management for dysvascular amputation in individuals with diabetes mellitus, with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-28Clinical Trial Results: A Sugar-Sweetened Beverage Reduction Intervention for Native American Men [NA]
Completed clinical trial evaluating a sugar-sweetened beverage reduction intervention among Native American men; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Update: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers [Phase 2, Phase 3]
Phase 2/3 trial update comparing pharmacokinetics and pharmacodynamics of a proposed insulin aspart biosimilar/interchangeable (I004) to Nov…
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Results: Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes [NA]
A completed clinical trial evaluating a lifestyle program (Walk, Dance, and Tone Your Abs) to reduce diabetes risk in adults with obesity; r…
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis [NA]
A completed clinical trial evaluating transcutaneous electrical acustimulation (TEA) for gastroparesis with diabetes mellitus with results p…
-
CLINICAL_TRIALS trial_result · 2026-07-15Clinical Trial Results: Social Risk Score, Clinical Decision Support Tool and Closed Loop Referral for Social Risk Screen and Referral [NA]
Completed clinical trial evaluating a social risk score, a clinical decision support tool, and closed-loop referral for social risk screenin…
-
EMA approval · 2026-07-13EMA Authorised: Lyumjev (previously Liumjev) (insulin lispro) — Eli Lilly Nederland B.V.
Lyumjev (insulin lispro) has been authorised in the EU for diabetes mellitus, with Eli Lilly Nederland B.V. as the marketing authorisation h…
-
EMA approval · 2026-07-13EMA Authorised: Abasaglar (previously Abasria) (insulin glargine) — Eli Lilly Nederland B.V.
EMA authorised Abasaglar (insulin glargine) for diabetes mellitus, with Eli Lilly Nederland B.V. as marketing authorization holder.
-
EMA approval · 2026-07-13EMA Authorised: Humalog (insulin lispro) — Eli Lilly Nederland B.V.
Humalog (insulin lispro) by Eli Lilly Nederland B.V. has been authorised for use in the European Union for diabetes mellitus.
-
EMA approval · 2026-07-10EMA Authorised: Ozempic (semaglutide) — Novo Nordisk A/S
The EMA has authorised Ozempic (semaglutide) by Novo Nordisk A/S for therapeutic use in diabetes mellitus.
-
EMA approval · 2026-07-03EMA Authorised: Zegalogue (dasiglucagon hydrochloride) — Zealand Pharma A/S
Zegalogue (dasiglucagon hydrochloride) has been authorised by the EMA for the treatment of Diabetes Mellitus.
-
EMA approval · 2026-07-01EMA Authorised: Ondibta (insulin glargine) — Gan & Lee Pharmaceuticals Europe GmbH
EMA authorised Ondibta, an insulin glargine product, for diabetes mellitus by Gan & Lee Pharmaceuticals Europe GmbH.
-
CLINICAL_TRIALS trial_result · 2026-06-16Clinical Trial Results: Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating allogeneic mesenchymal stem cell infusion therapy for endothelial dysfunction in diabetic patients with symptom…
-
EMA approval · 2026-06-10EMA Authorised: Bysumlog (insulin lispro) — Gan & Lee Pharmaceuticals Europe GmbH
The EMA has authorised Bysumlog (insulin lispro) for diabetes mellitus, under Gan & Lee Pharmaceuticals Europe GmbH.
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Results: Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease [NA]
A completed clinical trial evaluating iron reduction as a treatment approach for diabetes and nonalcoholic fatty liver disease.
-
EMA withdrawal · 2026-06-05EMA Application withdrawn: Insulin Aspart Injection (insulin aspart) — Masuu Pharma Europe Limited
The EMA withdrew the application for insulin aspart injection by Masuu Pharma Europe Limited.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight [Phase 3]
A Phase 3 trial investigating the weight loss effect of NNC0487-0111 in adults with overweight/obesity and type 2 diabetes (recruiting).
-
EMA approval · 2026-04-24EMA Authorised: Ondibta (insulin glargine) — Gan & Lee Pharmaceuticals Europe GmbH
EMA authorised Ondibta, a brand-name insulin glargine, for treating diabetes mellitus; Marketing Authorisation Holder is Gan & Lee Pharmaceu…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human [Phase 1]
A Phase 1 trial completed to evaluate potential drug interaction between metformin tablets and HRS-7535 tablets in healthy volunteers.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Taste Bud-Derived Stem Cells in Humans
A clinical trial is investigating taste bud–derived stem cells in humans for diabetes, with recruitment currently ongoing.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women [Phase 1]
Phase 1 pharmacokinetic study evaluating vitamin E (tocopherol) absorption and biomarkers in normal-weight and obese women.